Improved benefit of continuing luspatercept therapy: sub-analysis of patients with lower-risk MDS in...
Improved benefit of continuing luspatercept therapy: sub-analysis of patients with lower-risk MDS in the MEDALIST study
About this item
Full title
Author / Creator
Germing, Ulrich , Fenaux, Pierre , Platzbecker, Uwe , Buckstein, Rena , Santini, Valeria , Díez-Campelo, María , Yucel, Aylin , Tang, Derek , Fabre, Shannon , Zhang, George , Zoffoli, Roberto , Ha, Xianwei , Miteva, Dimana , Hughes, Christina , Komrokji, Rami S. , Zeidan, Amer M. and Garcia-Manero, Guillermo
Publisher
Berlin/Heidelberg: Springer Berlin Heidelberg
Journal title
Language
English
Formats
Publication information
Publisher
Berlin/Heidelberg: Springer Berlin Heidelberg
Subjects
More information
Scope and Contents
Contents
Red blood cell transfusion independence (RBC-TI) is an important goal in treating lower-risk myelodysplastic syndromes with ring sideroblasts. In the phase 3 MEDALIST study, RBC-TI of ≥ 8 weeks was achieved by significantly more luspatercept- versus placebo-treated patients in the first 24 weeks of treatment. In this post hoc analysis, we evaluated...
Alternative Titles
Full title
Improved benefit of continuing luspatercept therapy: sub-analysis of patients with lower-risk MDS in the MEDALIST study
Authors, Artists and Contributors
Identifiers
Primary Identifiers
Record Identifier
TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_9889415
Permalink
https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_9889415
Other Identifiers
ISSN
0939-5555
E-ISSN
1432-0584
DOI
10.1007/s00277-022-05071-8
